Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) ended Friday session in green amid volatile trading. The shares closed up +0.06 points or 0.90% at $6.75 with 1.67 million shares getting traded. Post opening the session at $6.70, the shares hit an intraday low of $6.60 and an intraday high of $6.85 and the price vacillated in this range throughout the day. The company has a market cap of $959.44 million and the numbers of outstanding shares have been calculated to be 142.14 million shares.
Amicus Therapeutics, Inc. (FOLD) announced that Chip Baird, Chief Financial Officer, will participate in a corporate overview and fireside chat at the Robert W. Baird & Co. 2016 Healthcare Conference in New York, NY on Wednesday, September 7 at 3:10pm ET.
An audio webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate website at http://ir.amicusrx.com/events.cfm, and will be archived for 90 days.
Shares of Alphatec Holdings Inc (NASDAQ:ATEC) ended Friday session in green amid volatile trading. The shares closed up +0.36 points or 8.72% at $4.49 with 1.01 million shares getting traded. Post opening the session at $4.99, the shares hit an intraday low of $4.17 and an intraday high of $4.99 and the price vacillated in this range throughout the day. The company has a market cap of $39.60 million and the numbers of outstanding shares have been calculated to be 8.56 million shares.
Alphatec Holdings Inc (ATEC) on Sept. 01, 2016 announced the completion of the previously announced sale of its international operations and distribution channel to Globus Medical (GMED), a leading musculoskeletal implant manufacturer.
With the closing of the transaction, the Company is now focused solely on the U.S. market, which Alphatec believes constitutes nearly 65% of the world’s spinal fusion market.
Over the past several years, the Company has focused its R&D programs and invested in the development of a leading, robust suite of products that are available to surgeons in the U.S. including Arsenal™ Degenerative, Arsenal Deformity and Battalion™ Universal Interbody. In addition, the Company has recently obtained U.S. clearance for its new XYcor® Expandable Spinal Spacer System, which the Company plans to launch later this year. The Company also made significant progress through its initiative to outsource its manufacturing operations—reducing capital investment in equipment, partnering with valued suppliers to provide flexible capacity, while achieving unit level cost reductions and margin improvements. As a result, Alphatec believes it is now better positioned to compete more effectively in the marketplace, accelerate growth and continue to improve profitability.
“Today marks the beginning of a new chapter for Alphatec,” said Jim Corbett, President and Chief Executive Officer of Alphatec Spine. “I am excited about the long-term prospects for the company as we pursue the U.S. spinal market with the resources we need to support continued investment in the commercialization of our robust product line. We have the right products, an exceptional team and a newly streamlined balance sheet to support our growth across the country, and we look forward to executing on our vision.”